Krasner, Carolyn N.

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer

Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 395

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer

Krasner, C. N., Campos, S. M., Young, C. L., Chadda, K. R., Lee, H., Birrer, M. J., Horowitz, N. S., Konstantinopoulos, P. A., D'Ascanio, A. M., Matulonis, U. A., et al. (2021) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentCancer therapeutics and mechanisms

Cited by 42

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer

Penson, R. T., Ambrosio, A. J., Whalen, C. A., Krasner, C. N., Konstantinopoulos, P. A., Bradley, C., Matulonis, U. A., & Birrer, M. J. (2023) · The Oncologist

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 12